OptiNose (NASDAQ:OPTN) Receives “Buy” Rating from HC Wainwright

OptiNose (NASDAQ:OPTN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $5.00 price target on the stock.

OptiNose Trading Down 10.3 %

NASDAQ OPTN opened at $0.46 on Wednesday. The company has a market cap of $68.60 million, a price-to-earnings ratio of -1.60 and a beta of -0.07. The company has a 50 day moving average of $0.76 and a 200-day moving average of $0.96. OptiNose has a 1-year low of $0.44 and a 1-year high of $2.10.

Institutional Investors Weigh In On OptiNose

Institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in shares of OptiNose in the 3rd quarter valued at approximately $61,000. XTX Topco Ltd acquired a new position in OptiNose during the second quarter valued at approximately $88,000. Squarepoint Ops LLC lifted its stake in OptiNose by 173.7% during the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after purchasing an additional 108,903 shares during the last quarter. Oracle Investment Management Inc. acquired a new stake in shares of OptiNose in the 1st quarter valued at $474,000. Finally, Rice Hall James & Associates LLC boosted its holdings in shares of OptiNose by 15.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company’s stock valued at $764,000 after purchasing an additional 152,435 shares in the last quarter. Institutional investors own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.